• Horizon Gets Early FDA OK for First Thyroid Eye Disease Treatment

    25 days ago - By Xconomy

    The first treatment for a rare disease that causes eye bulging and double vision received an FDA nod on Tuesday, weeks ahead of the agency's March 8 deadline to review the drug. Dublin, Ireland-based Horizon Therapeutics tested the medicine, teprotumumab-trbw , in thyroid eye disease, which occurs when the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards. In addition to causing physical discomfort and impaired vision that can impair daily activities, the autoimmune condition can also cause facial disfigurement. In two...
    Read more ...